...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Prostate Trial

I suppose frustration getting the better of me,but I wrote IR today to enquire wether the shareholders of the company were entitled to be advised of the results of the combo prostate trial.The trial concluded Oct 2019 with results expected Nov2019.We are now 5 months beyond that date.This is not a public listed company so some rules are different but it seems to me that owners have rights to information.

Share
New Message
Please login to post a reply